MXCT
NEUTRALBlackRock Increases Stake in MaxCyte
The major investor BlackRock has increased its stake in the medical device company MaxCyte.
MaxCyte, Inc.
165.00GBX
-2.94%
Market Cap
209.48M
Volume
0% of avg
P/E Ratio
-5.50
EPS (TTM)
-0.3
Beta
1.13
Day Range
165.00p - 165.00p
52 Week Range
160.00p165.00p407.84p
165.00p
Upcoming Events
MXCT
NEUTRALMaxCyte Announces Change in Substantial Shareholding
The healthcare company has received a notification of a change in substantial shareholding from BlackRock, Inc.
MXCT
NEUTRALMaxCyte Files Q1 2025 Form 10-Q
The healthcare company has filed its quarterly financial report with the SEC.
MXCT
NEUTRALMaxCyte Reports Q1 2025 Results, Reiterates Full Year Guidance
The medical device company reported a 1% increase in Q1 core revenue, with a healthy cash position but high valuation. Investors may view the results neutrally given the modest growth.
MXCT
BADMaxCyte Files Definitive Proxy Statement for AIM Delisting
The healthcare technology company has filed a definitive proxy statement to seek shareholder approval for the cancellation of its shares from trading on the AIM market.
MXCT
NEUTRALMaxCyte Announces Director Shareholding Change
The healthcare company has announced a change in a director's shareholding.
MXCT
NEUTRALMaxCyte Announces Regulatory Threshold Crossing by BlackRock
The healthcare company has announced that BlackRock has crossed a regulatory threshold in its shareholding.
MXCT
NEUTRALBlackRock Increases Stake in MaxCyte
The healthcare technology company reports that BlackRock has increased its stake in the business.
MXCT
GOODMaxCyte Announces Proposed Cancellation of AIM Listing
The medical device company plans to cancel its AIM listing to focus on its Nasdaq listing, which it believes will enhance liquidity and reduce costs.
MXCT
NEUTRALMaxCyte Announces Regulatory Threshold Crossing by BlackRock
The healthcare company reports a regulatory threshold crossing by major investor BlackRock.